Membranous Nephropathy (MN) is the leading cause of nephrotic syndrome in adults. Primary or idiopathic Membranous Nephropathy (iMN) has been considered as an organ-specific autoimmune disease with an unknown aetiology. By contrast, secondary membranous nephropathy has been described as the expression of a systemic autoimmune response to malignancy or bacterial/viral infections. In the majority of iMN cases, glomerular lesions are determined by autoantibodies against a podocyte membrane protein, the M-type of phospholipase A2 receptor 1 (PLA2R1). Several studies have suggested that the detection of anti-PLA2R1 in patients sera with nephrotic syndrome may be pathognomonic of iMN, thus obviating the need for a diagnostic renal biopsy and an extensive workup for underlying causes. Many authors inferred that the measurement of anti-PLA2R1 may change the diagnostic algorithm in patients with nephrotic syndrome and guide treatment decisions in patients with iMN. Measurement of anti-PLA2R1 antibodies is now possible through an easy to use, commercially available assay. The aim of this review is to describe the clinical relevance of anti-PLA2R1 assessment in patients with MN, and to extensively discuss the biotechnological methods available to measure them.

Anti-Phospholipase A2 Receptor Antibodies in Membranous Nephropathy : from Bench to the Patient / R. Assandri, A. Montanelli, M. Monari, M.A. Podestà, G. Graziani. - In: JOURNAL OF NEPHROLOGY & THERAPEUTICS. - ISSN 2161-0959. - 4:2(2014 Mar 20), pp. 1000155.1-1000155.6. [10.4172/2161-0959.1000155]

Anti-Phospholipase A2 Receptor Antibodies in Membranous Nephropathy : from Bench to the Patient

M.A. Podestà;G. Graziani
Ultimo
2014

Abstract

Membranous Nephropathy (MN) is the leading cause of nephrotic syndrome in adults. Primary or idiopathic Membranous Nephropathy (iMN) has been considered as an organ-specific autoimmune disease with an unknown aetiology. By contrast, secondary membranous nephropathy has been described as the expression of a systemic autoimmune response to malignancy or bacterial/viral infections. In the majority of iMN cases, glomerular lesions are determined by autoantibodies against a podocyte membrane protein, the M-type of phospholipase A2 receptor 1 (PLA2R1). Several studies have suggested that the detection of anti-PLA2R1 in patients sera with nephrotic syndrome may be pathognomonic of iMN, thus obviating the need for a diagnostic renal biopsy and an extensive workup for underlying causes. Many authors inferred that the measurement of anti-PLA2R1 may change the diagnostic algorithm in patients with nephrotic syndrome and guide treatment decisions in patients with iMN. Measurement of anti-PLA2R1 antibodies is now possible through an easy to use, commercially available assay. The aim of this review is to describe the clinical relevance of anti-PLA2R1 assessment in patients with MN, and to extensively discuss the biotechnological methods available to measure them.
Settore MED/14 - Nefrologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
antiphospholipase-a-receptor-antibodies-in-membranous-nephropathyfrom-bench-to-the-patient-2161-0959.1000155.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 792.77 kB
Formato Adobe PDF
792.77 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/747791
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact